Current Status of Natural Products/siRNA Co-Delivery for Cancer Therapy

被引：0

作者：

Jacob, Megha Mariya ^{[1
]}

Santhosh, Amritha ^{[1
]}

Rajeev, Anjaly ^{[1
]}

Joy, Reshma ^{[1
]}

John, Pooja Mary ^{[1
]}

John, Franklin ^{[1
]}

George, Jinu ^{[1
]}

机构：

[1] Sacred Heart Coll Autonomous, Dept Chem, Bioorgan Chem Lab, Kochi 682013, Kerala, India

来源：

CHEMISTRYSELECT | 2022年 / 7卷 / 44期

关键词：

anticancer therapy; co-delivery platforms; nanocarriers; natural products; small interfering RNA; CALCIUM-PHOSPHATE NANOPARTICLES; DRUG-RESISTANCE; GENE DELIVERY; TUMOR MICROENVIRONMENT; CATIONIC LIPOSOMES; MESOPOROUS SILICA; RECENT PROGRESS; URSOLIC ACID; VEGF SIRNA; CURCUMIN;

D O I：

10.1002/slct.202203476

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

siRNA interference is a conserved cellular gene silencing mechanism and a viable technique for human disease intervention, including cancer. This method has significant potential benefits over currently available treatments. The limitations of using siRNA-based systems are the lack of specificity, high chance of degradation, toxicity, and ineffective cellular uptake. Combination therapy using natural compounds possesses higher therapeutical value with siRNA. Various natural compounds are used in cancer treatments such as paclitaxel, ursolic acid, hypericin, etoposide, etc due to their diverse bioactivities. In this review, the codelivery of natural compounds/siRNA using nanovehicles is highlighted.

引用

页数：14

共 50 条

[1] Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy
Ashrafizadeh, Milad
Zarrabi, Ali
Hushmandi, Kiavash
Hashemi, Farid
Moghadam, Ebrahim Rahmani
Raei, Mehdi
Kalantari, Mahshad
Tavakol, Shima
Mohammadinejad, Reza
Najafi, Masoud
Tay, Franklin R.
Makvandi, Pooyan
ACS COMBINATORIAL SCIENCE, 2020, 22 (12) : 669 - 700
[2] Co-Delivery of siRNA and Docetaxel to Cancer Cells by NLC for Therapy
Senel, Behiye
Basaran, Ebru
Akyil, Evrim
Guven, Umay Merve
Buyukkoroglu, Gulay
ACS OMEGA, 2024, 9 (10): : 11671 - 11685
[3] The importance of co-delivery of nanoparticle-siRNA and anticancer agents in cancer therapy
Khelghati, Nafiseh
Soleimanpour Mokhtarvand, Jafar
Mir, Mostafa
Alemi, Forough
Asemi, Zatollah
Sadeghpour, Alireza
Maleki, Masomeh
Samadi Kafil, Hossein
Jadidi-niaragh, Farhad
Majidinia, Maryam
Yousefi, Bahman
CHEMICAL BIOLOGY & DRUG DESIGN, 2021, 97 (04) : 997 - 1015
[4] Direct cytosolic co-delivery of siRNA and tamoxifen for enhanced breast cancer therapy
Hardie, Joseph
Jiang, Ying
Tetrault, Emily
Ghazi, Phaedra
Tonga, Gulen Yesilbag
Farkas, Michelle
Rotello, Vincent
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
[5] Co-delivery of paclitaxel and survivin siRNA with cationic liposome for lung cancer therapy
Zhang, Chuanmin
Zhang, Shubiao
Zhi, Defu
Zhao, Yinan
Cui, Shaohui
Cui, Jingnan
COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS, 2020, 585 (585)
[6] Efficient and Specific Co-Delivery of Vimentin siRNA and Doxorubicin with Aptamosomes for Combination Cancer Therapy
Kim, Keun-Sik
Lee, Gwang-Hyun
Jeong, Hwa Yeon
Park, Yong Serk
Kim, Dong-Eun
MOLECULAR THERAPY, 2012, 20 : S158 - S158
[7] Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy
Xiao, Bo
Ma, Lijun
Merlin, Didier
EXPERT OPINION ON DRUG DELIVERY, 2017, 14 (01) : 65 - 73
[8] Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents
Zhao, Jing
Feng, Si-Shen
NANOMEDICINE, 2015, 10 (14) : 2199 - 2228
[9] Co-Delivery of Paclitaxel and siRNA with pH-Responsive Polymeric Micelles for Synergistic Cancer Therapy
Shi, Liuqi
Feng, Huayang
Li, Zhanrong
Shi, Jun
Jin, Lin
Li, Jingguo
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 2021, 17 (02) : 322 - 329
[10] Co-Delivery of Doxorubicin and siRNA with Reduction and pH Dually Sensitive Nanocarrier for Synergistic Cancer Therapy
Chen, Weicai
Yuan, Yuanyuan
Cheng, Du
Chen, Jifeng
Wang, Lu
Shuai, Xintao
SMALL, 2014, 10 (13) : 2678 - 2687

← 1 2 3 4 5 →